Company news
Prothena Corporation plc news in 2023
Prothena Corporation plc's news releases, calls and decks from 2023, newest first.
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
November 1, 2023
Prothena to Report Third Quarter 2023 Financial Results on November 2
October 25, 2023
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
August 2, 2023
Prothena to Report Second Quarter 2023 Financial Results on August 3
July 26, 2023
Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody
July 9, 2023
Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab
June 26, 2023
Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors
May 15, 2023
Prothena Reports First Quarter 2023 Financial Results and Business Highlights
May 3, 2023
Prothena to Report First Quarter 2023 Financial Results on May 4
April 26, 2023
Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023
March 30, 2023
Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
February 22, 2023
Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
February 15, 2023
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 2, 2023
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
January 30, 2023
Calls in 2023
Decks in 2023
- Technical Presentation (March 2023)
Technical · 12 slides · Mar 31, 2023